Loading...
Loading...
Browse all stories on DeepNewz
VisitMajor pharmaceutical partnership with Amgen for BLINCYTO® by mid-2025?
Yes • 50%
No • 50%
Official press releases from Amgen or partner companies
Amgen's BLINCYTO® Improves Survival in Pediatric B-Cell ALL: AALL1731 Results at ASH24
Dec 8, 2024, 02:04 PM
At the American Society of Hematology's (ASH) 2024 Annual Meeting (#ASH24), significant clinical trial results were presented, highlighting advancements in the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). A key study presented by the Children's Oncology Group (COG) revealed that the addition of blinatumomab, marketed as BLINCYTO® by Amgen, to induction chemotherapy significantly improved disease-free survival in children with standard-risk B-ALL. The full results of the AALL1731 trial demonstrated enhanced survival rates when blinatumomab was added to chemotherapy regimens for newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia.
View original story
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Yes • 50%
No • 50%
Roche • 25%
Pfizer • 25%
AstraZeneca • 25%
No new partnership • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Increase by more than 20% • 25%
Increase by less than 10% • 25%
Increase between 10% and 20% • 25%
No significant increase • 25%
Other • 25%
The New England Journal of Medicine • 25%
The Lancet • 25%
JAMA • 25%